Table 2 Main results of meta-analysis
No. of studies | Patients | Heterogeneity test (I2, P) | Combined estimate (95 % CI)/P value | ||
|---|---|---|---|---|---|
Fixed-effect model | Random-effect model | ||||
Overall patients | |||||
OS | 10 | 685 | 15.4 %, 0.302 | HR 2.05 (1.51–2.77)/<0.001 | HR 2.10 (1.50–2.95)/<0.001 |
DFS | 8 | 359 | 0.0 %, 0.768 | HR 2.05 (1.55–2.70)/<0.001 | HR 2.05 (1.55–2.70)/<0.001 |
MET | 6 | 363 | 0.0 %, 0.632 | RR 3.21 (2.13–4.84)/<0.001 | RR 2.79 (1.89–4.12)/<0.001 |
Osteosarcoma | |||||
OS | 4 | 270 | 0.0 %, 0.692 | HR 2.32 (1.47–3.66)/<0.001 | HR 2.32 (1.47–3.66)/<0.001 |
DFS | 3 | 138 | 0.0 %, 0.473 | HR 2.43 (1.16–5.09)/0.018 | HR 2.43 (1.16–5.09)/0.018 |
Soft tissue sarcoma | |||||
OS | 5 | 381 | 47.8 %, 0.105 | HR 1.68 (1.07–2.63)/0.025 | HR 1.94 (0.98–3.83)/0.055 |
DFS | 3 | 136 | 0.0 %, 0.657 | HR 2.06 (1.41–3.02)/<0.001 | HR 2.06 (1.41–3.02)/<0.001 |
Chondrosarcoma | |||||
OS | 1 | 34 | – | HR 2.83 (1.11–7.22)/0.030 | HR 2.83 (1.11–7.22)/0.030 |
DFS | 2 | 85 | 29.7 %, 0.233 | HR 1.87 (1.15–3.04)/0.011 | HR 1.96 (1.06–3.64)/0.033 |